Tymlos FDA Approval and Mechanism of Action

The U.S. Food and Drug Administration (FDA) has granted final approval for the New Drug Application (NDA 208743) of Tymlos (abaloparatide), an osteoporosis treatment developed by Radius Health. Tymlos is a parathyroid hormone-related protein (PTHrP) analog that selectively acts on the type 1 parathyroid hormone receptor (PTH1R), directly stimulating the activity of osteoblasts, the bone-forming cells. Unlike existing standard treatments, such as bisphosphonate-based bone resorption inhibitors, Tymlos is an anabolic agent that actively promotes new bone formation, which has garnered significant attention in the market. In particular, it has been recognized for its innovative approach in providing a powerful clinical alternative for postmenopausal women who are at extremely high risk of fractures, enabling them to rapidly restore bone density.

Expansion of Indication to Male Osteoporosis and Clinical Results

Since its initial approval, Tymlos has consistently expanded its clinical applications, and in December 2022, it received FDA expanded approval as a treatment for men with osteoporosis at high risk of fractures. This expansion of indication is based on the results of the Phase 3 clinical trial, the ATOM study, which demonstrated that in male patients who received Tymlos for 12 months, spinal and hip bone mineral density (BMD) significantly increased compared to the control group. This represents a significant milestone in providing a new treatment option for male osteoporosis patients, who have historically had relatively limited treatment options. In addition, it is developed as a once-daily subcutaneous injection, which offers the convenience of self-administration.

Global Osteoporosis Market Size and Competitive Landscape

The global osteoporosis treatment market is estimated to be a large market, ranging from approximately $15.2 billion to $17.4 billion by 2025-2026. In the market, Tymlos competes fiercely with Eli Lilly's Forteo (teriparatide), Amgen's Evenity (romosozumab), and Prolia (denosumab). In 2021 alone, Tymlos recorded annual net sales of approximately $219 million, establishing a strong presence. It has been driving the influx of new patients by leveraging its superior price competitiveness and clinical efficacy compared to Forteo. Recently, the sequential therapy approach, in which bone-forming agents are first prescribed to patients at high risk of fractures, followed by bone resorption inhibitors, has become established in clinical practice, further highlighting the value of Tymlos.

Radius Health's M&A and Strategic Investment Value

Recognizing the commercial value of Tymlos, Radius Health was acquired by a consortium of Gurnet Point Capital and Patient Square Capital in August 2022 for approximately $890 million, resulting in a voluntary delisting. The transaction included a contingent value right (CVR) that would provide an additional $1 per share if Tymlos' annual net sales exceeded $300 million before the end of 2025, which has attracted significant investor interest. Even after transitioning to a private company, Tymlos continues to serve as a core asset that generates stable cash flow, and it has recently maximized sales synergies through a merger with Paratek Pharmaceuticals. This is a prime example of how a commercial-stage bio asset with clinical and regulatory risks removed is an attractive investment target in the private equity market.